Prognostic value of C-reactive protein/albumin ratio in ST-segment elevation myocardial infarction

Area of Science:

• Biomarkers and Disease Prognosis
• Cardiovascular Medicine
• Critical Care Medicine

Background:

• Inflammatory biomarkers are increasingly vital for screening and prognosis in coronary artery disease (CAD).
• Serum albumin and C-reactive protein (CRP) are individually assessed, but their ratio may offer enhanced predictive value.

Purpose of the Study:

• To evaluate the prognostic efficacy of the C-reactive protein (CRP)/albumin ratio (CAR) in critical diseases.
• To determine if CAR is a more precise predictor of mortality in ST-segment elevation myocardial infarction (STEMI) than CRP or albumin alone.

Main Methods:

• Analysis of serum C-reactive protein (CRP) and albumin levels.
• Calculation of the C-reactive protein/albumin ratio (CAR) as an ischemia-dependent risk index.
• Assessment of CAR as an independent marker for in-hospital and long-term all-cause mortality in STEMI patients undergoing percutaneous coronary intervention.

Main Results:

• The CAR demonstrated higher precision in determining prognosis for critical diseases compared to individual CRP or albumin levels.
• CAR was identified as an independent predictor of both in-hospital and long-term all-cause mortality in STEMI patients.
• The study confirmed CAR as a more effective prognostic marker than either CRP or albumin used separately.

Conclusions:

• The C-reactive protein/albumin ratio (CAR) offers superior prognostic value in critical illness and acute myocardial infarction.
• CAR serves as a valuable and independent risk index for predicting mortality in cardiovascular emergencies.
• Clinical application of CAR can enhance risk stratification and patient management in critical care settings.